February 03, 2023

Have you ever had a heart attack or stroke? Do you have poor circulation?

The University of Alabama at Birmingham (UAB), in collaboration with Novo Nordisk, is conducting a 3-year research study to see if CagriSema, an investigational weekly medicine being studied for the treatment of obesity is also safe for the heart and blood vessels.

We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.

You may qualify to participate if::
  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
  • arterial disease)
  • You are 55 years of age or older
  • You are living with obesity (BMI ≥ 30 kg/m2 )
  • You can have type 2 diabetes and/or chronic kidney disease
  • You are able to attend regular clinic visits and receive phone calls over
  • a period of 3 years

Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu